Table 1.
Patient demographics in the large, randomized roflumilast treatment trials
| Rabe 200562 | Calverley 200763 | Calverley 200965 |
Fabbri 200968 |
||
|---|---|---|---|---|---|
| Salmeterol | Tiotropium | ||||
| Number randomized | 1411 | 1513 | 3096 | 933 | 743 |
| Mean age (years) | 64 | 65 | 64 | 65 | 64 |
| % male | 74 | 76 | 75 | 66 | 72 |
| Smoking history (pack years) | 43 | 44 | 48 | 43 | 43 |
| Current smokers (%) | 46 | 37 | 41 | 39 | 40 |
| FEV1 prebronchodilator | 1.4 | 1.0 | 1.0 | 1.4 | 1.5 |
| FEV1 (% predicted) | 54 | 37 | 33 | 52 | 53 |
Notes: Data include number of patients randomized in each trial, mean age in years of patients in each trial, percentage of male patients, average smoking history in pack years (one pack year = one pack/day for one year), percentage of current smokers, mean prebronchodilator FEV1, and mean FEV1 as a percentage of the predicted value.
Abbreviation: FEV1, forced expiratory volume in one second.